Newly published economic modeling concludes that Perspectum’s proprietary biomarker cT1 may help US Veterans Administration (VA) health care enrollees gain better access and treatment for MASH (metabolic dysfunction-associated steatohepatitis), an advanced stage of MASLD (metabolic dysfunction-associated steatotic liver disease).

Hancock et al’s study, published in the Journal of Medical Economics, evaluated different care pathways for MASH, and finds that LiverMultiScan’s corrected T1 (cT1) is the best way to diagnose and monitor widespread adoption of the first FDA-approved MASH treatment, resmetirom, in the VA health care population. The study sought to address two major VA health care issues US lawmakers and patient advocacy groups alike have been grappling with since the March 2024 FDA resmetirom approval. One issue is a lack of clinical guidelines on the most cost-effective strategies for treating and monitoring patients with metabolic liver disease. The second is addressing the currently stringent VA guidelines which require a patient to have a liver biopsy to confirm MASH in order to receive resmetirom.

Key findings of the study, that evaluated the budgetary impact of pathways using cT1 versus liver biopsy or VCTE (vibration controlled transient elastography) to assign suspected MASH patients to resmetirom treatment, and monitor response, showed that cT1 resulted in the lowest per-patient costs in VA enrollees ($7,022 for cT1 vs $7,268 for biopsy vs $28,509 for VCTE). These results remained consistent across scenario analyses and for Medicare beneficiaries.

Perspectum CEO, Rajarshi Banerjee, said, “The study data show comparable accuracy and precision of LiverMultiScan to biopsy, without the additional cost of harm to veterans.” Dr. Banerjee continued, “With early identification, treatment and appropriate management, advanced liver disease progression can be avoided or reduced significantly with added cost savings.”

Dr. Jose Vargas MD PhD, Associate Professor of Medicine at Georgetown University and study co-author, said, “I hope the study findings will pave the way for more budget impact studies looking at the value of next generation artificial intelligence enabled non-invasive technologies (NITs). The new classes of liver disease drugs and therapeutics and newly available NITs complement each other beautifully as they have co-evolved, starting in clinical trials, to meet current societal unmet needs.”

Dr Banerjee added, “It is very important for lawmakers to know what the best available care options are for veterans and enrollees in other publicly funded health care programs. We have conclusively established LiverMultiScan’s clinical relevance in liver disease detection, assessment, treatment planning and monitoring. Now we are demonstrating how Perspectum can play a role in lowering costs while improving outputs and quality in publicly funded health care programs. Artificial intelligence (AI) and other technologies can also enable cost savings in the management of chronic disease within Medicare and other publicly funded health care programs, aligning with the commitment to improving the health of Americans.”

About Perspectum:

Perspectum, a global medical technology company, with offices in the US and UK, delivers leading digital technologies that help clinicians provide better care for patients with chronic metabolic disease, multi-organ diseases, and cancer. With a strong focus on precision medicine using advanced imaging, our vision is to empower patients and clinicians through quantitative assessments of health enabling early detection, diagnosis, monitoring, and targeted treatment. With a diverse team of physicians, biomedical scientists, engineers, and technologists, Perspectum offers a way to manage complex health problems at scale.

About LiverMultiScan:

LiverMultiScan is a commercially available, FDA cleared software medical device (SaMD) intended for diagnosis, monitoring, and clinical management of patients with liver diseases. It is a non-invasive, non-contrast, and safe technology that assesses liver disease activity, fat, and iron using existing MRI infrastructure, and provides visually enhanced patient friendly results. Many research studies and peer reviewed publications demonstrate the clinical utility of LiverMultiScan in the diagnosis and monitoring of liver diseases such as MASH/MASLD, autoimmune hepatitis, and viral hepatitis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250901262046/en/